Drugs / Bivalent HPV vaccine
Bivalent HPV vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05291845 | Apr 2022 → Oct 2025 overdue | common wart, human papilloma virus infection | Zagazig University | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07281677 | Dec 2025 → Dec 2028 expected | human papilloma virus infection | Zhejiang Provincial Center for Disease Control and Prevention | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04235257 | Nov 2020 → Dec 2026 expected | human papilloma virus infection | University of Washington | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bivalent HPV vaccine | “Bivalent HPV vaccine” NCT04235257 ↗ |
| Known as | Cecolin | “2vhpv\[Cecolin\]-9vhpv\[Cecolin 9\]” NCT07281677 ↗ |
| Known as | Cervarix | “Cervarix (GlaxoSmithKline, Brentford, UK), a recombinant bivalent human papillomavirus (HPV) vaccine, has shown promising efficacy in the treatment of warts.” PMID 31369771 ↗ Jul 2019 |
| Modality | Vaccine | “Bivalent HPV vaccine” NCT04235257 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT04235257 ↗ |